Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells WithPIK3CAMutations and Overcoming Strategies

28 Apr 2025

Abstract excerpt

Background/Aim: Alpelisib has shown promise in preclinical studies for treating PIK3CA-mutant gastric cancer (GC), and its combination with chemotherapy has progressed to clinical trials. However, acquired resistance to alpelisib remains a significant challenge. This study aimed to elucidate the mechanisms underlying acquired alpelisib resistance and propose potential therapeutic strategies to overcome it....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Gastrointestinal Tumor Research and Treatment
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40295072
DOI: 10.21873/anticanres.17567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells WithPIK3CAMutations and Overcoming StrategiesPMID 40295072Read ↗

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.Semantic proximity Read ↗

The CAGE–MiR-181b-5p–S1PR1 Axis Regulates Anticancer Drug Resistance and Autophagy in Gastric Cancer CellsSemantic proximity Read ↗

Identifying therapeutic targets in gastric cancer: the current status and future direction.Semantic proximity Read ↗

Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaSemantic proximity Read ↗

Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancerSemantic proximity Read ↗

CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.Semantic proximity Read ↗

Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.Semantic proximity Read ↗

Reduced 4E-BP1 activity leads to acquired capivasertib resistance via increased cap-dependent protein synthesisSemantic proximity Read ↗

S1PR1 predicts patient survival and promotes chemotherapy drug resistance in gastric cancer cells through STAT3 constitutive activationSemantic proximity Read ↗

Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinibSemantic proximity Read ↗

PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell–like Traits and Multiple BiomarkersSemantic proximity Read ↗

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.